China Approves Lilly's Orforglipron, the First GLP-1 Weight-Loss Pill Cleared There
China's medicines regulator approved Eli Lilly's orforglipron on November 12, making it the first GLP-1 pill approved in China for weight loss, Reuters reported; until now, Chinese regulators had approved GLP-1 drugs for weight management only as injections. Lilly, which sells the drug as Foundayo in the U.S., did not comment on price. Novo Nordisk's application for its oral Wegovy was accepted in August. A J.P. Morgan analyst has forecast that annual sales of GLP-1 weight-management drugs in China could reach 30 billion yuan ($4.5 billion) within five to seven years, up from an estimated 3 billion to 4 billion yuan now.